Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Acquisitions & Divestments: 2019-2025

Historic Change in Acquisitions & Divestments for Dianthus Therapeutics (DNTH) over the last 4 years, with Sep 2025 value amounting to $78.6 million.

  • Dianthus Therapeutics' Change in Acquisitions & Divestments rose 313.53% to $78.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $305.3 million, marking a year-over-year increase of 408.86%. This contributed to the annual value of $127.0 million for FY2024, which is 63.27% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Change in Acquisitions & Divestments stood at $78.6 million, which was up 31.82% from $59.6 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Change in Acquisitions & Divestments registered a high of $85.0 million during Q4 2024, and its lowest value of $2.0 million during Q4 2022.
  • Over the past 3 years, Dianthus Therapeutics' median Change in Acquisitions & Divestments value was $21.9 million (recorded in 2023), while the average stood at $38.6 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first skyrocketed by 800.00% in 2023, then plummeted by 63.45% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $2.0 million in 2022, then spiked by 800.00% to $18.0 million in 2023, then skyrocketed by 372.22% to $85.0 million in 2024, then spiked by 313.53% to $78.6 million in 2025.
  • Its last three reported values are $78.6 million in Q3 2025, $59.6 million for Q2 2025, and $82.1 million during Q1 2025.